Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Endocyte, Inc.
Type
Public
Traded as NASDAQ: ECYT
Industry Biopharmaceutical
Founded 1996 (1996)
Headquarters West Lafayette, Indiana, United State
Key people
Mike Sherman, President and CEO
Number of employees
78
Website www.endocyte.com

Endocyte (NASDAQ: ECYT) is a biopharmaceutical company established in 1996 and headquartered in West Lafayette, Indiana, a resident of the Purdue Research Park. In 2011 the company completed successfully an initial public offering (IPO). As of 2013, the company had 93 employees. The original president and CEO, Ron Ellis, was succeeded by Mike Sherman, who held a CFO position at the company before this change in June 2016.

Endocyte is advancing the first technology platform for the creation of small molecule drug conjugates (a.k.a. SMDCs), which consist of a small molecule linked to a potent drug, and is developing a pipeline of SMDCs together with non-invasive companion imaging agents for cancer, inflammatory diseases and kidney disease (autosomal-dominant polycystic kidney disease/ADPKDor PKD). Endocyte’s lead drug candidate is vintafolide, an investigational targeted cancer therapeutic in late-stage development. In 2012 marketing rights were acquired by Merck for $120 million in an upfront payment and up to $880 million in milestone payments. Vintafolide is a small molecule drug conjugate consisting of a small molecule targeting the folate receptor, which is expressed on many cancers, such as ovarian cancer, and a potent chemotherapy drug, a derivative of vinblastine. Endocyte retained rights to the development and commercialization of etarfolatide.

Endocyte’s other preclinical drug candidates also target the folate receptor as well as prostate-specific membrane antigen (PSMA) receptors. The company was formed based on technology developed by Philip Low (the company's CSO), and Christopher Leamon, PhD, the company’s VP of research. This technology is a folic acid-based drug delivery system, referred to now as folate targeting. The company is also developing SMDCs with varying drug payloads as well as different ligands for other molecular targets, such as prostate-specific membrane antigen (PSMA) and has also developed, with Bristol-Myers Squibb, an epothilone-folic acid conjugate (BMS-753493), described at a 2008 conference.

Investment goal date:
Dividends reinvested
Endocyte, Inc. ECYT report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-09
--
--
Q4 2017
2018-03-07
--
--
Q4 2017
2018-03-05
--
--
Q3 2017
2017-11-06
--
--
Q3 2017
2017-11-06
-0.5500
0.0000
Q2 2017
2017-08-08
-0.2800
-0.2800
Q1 2017
2017-05-10
-0.2700
-0.2700
Q4 2016
2017-03-10
-0.2600
-0.2600
Q3 2016
2016-11-09
-0.2100
-0.2100
Q2 2016
2016-08-04
-0.3300
-0.3300
Q1 2016
2016-05-04
-0.2400
-0.2400
Q4 2015
2016-03-02
-0.2300
-0.2300
Q3 2015
2015-11-03
-0.2400
-0.2400
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BlackRock Fund Advisors
1280030
BlackRock Inc.
2009969
BlackRock Institutional Trust Company, N.A.
517159
BRIDGEWAY CAPITAL MANAGEMENT INC
195800
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM
258100
D. E. Shaw & Co., Inc.
317394
FMR LLC
3509035
GEODE CAPITAL MANAGEMENT, LLC
273757
JPMORGAN CHASE & CO
611043
NORTHERN TRUST CORP
396048
PINNACLE ASSOCIATES LTD
806516
RENAISSANCE TECHNOLOGIES LLC
192561
RMB Capital Management, LLC
264885
STATE STREET CORP
641476
Vanguard Group, Inc
1629836
Major Shareholders
Name Relationship
Total Shares
Holding stocks
MELDRUM PETER D
0.0200% (7800)
ECYT / MYGN /
APLIN JOHN C
0.0700% (28863)
ECYT /
BRAUER KEITH E
0.0400% (18271)
ECYT /
GODDARD COLIN
0.0200% (7800)
ECYT /
KOZIN MARC D
0.0200% (7800)
DYAX / ECYT / OVAS / UFPT /
MIDDLETON FRED A
0.4700% (194049)
ECYT / PCRX / STXS /
HANHAM ANN
0.0200% (7800)
ECYT / SCYX /
Russell Lesley
0.0200% (7800)
AMAG / ECYT / ENTA / TLOG /
Leamon Christopher P
0.3000% (124401)
ECYT /
Ellis P Ron
0.7700% (320040)
ECYT /
Lovejoy Chandra D
0.0200% (6250)
ECYT /
Ritter Allen R
0.0800% (34282)
ECYT /
Sherman Michael A.
0.8000% (333111)
ECYT / MJN /
Low Philip S
0.6900% (288605)
ECYT /
Taylor Beth
0.1500% (61283)
ECYT /
Nguyen Binh
0.0700% (28359)
ECYT /
Meek David D.
0.0200% (7500)
ECYT /
Harper Scot
0.0500% (22535)
ECYT /
Brinkley Michael A.
0.0600% (23486)
ECYT /
Parker Katherine
0.1500% (63109)
ECYT /
Armour Alison A.
0.2100% (89065)
ECYT /
% ()